What Celltrion does

Celltrion Inc. is a South Korean biopharmaceutical company founded in February 2002 and listed on the Korea Stock Exchange (ticker 068270). It is the developer of the world's first monoclonal antibody biosimilar (Remsima, infliximab) and operates Korea's largest biosimilar manufacturing footprint, with current drug-substance capacity of 250,000L at Songdo and a further 66,000L at its newly acquired Branchburg, New Jersey facility, scaling toward a planned 571,000L by 2030. The company also markets novel biologics (Zymfentra subcutaneous infliximab with route-of-administration patent protection to 2040), small-molecule products (CT-G07 for HIV, Donerion Patch for Alzheimer's), and an early-stage pipeline spanning ADC candidates (CT-P70, FDA Fast Track for lung cancer), bispecific T-cell engagers (ABP-102/CT-P72), and next-generation obesity candidates (CT-G32).

The portfolio architecture rests on a proprietary subcutaneous formulation platform, an in-house ADC platform, a multi-specific antibody platform, and an AI-based drug development organization that uses bioinformatics and partners with startups such as Galux for de novo antibody design. Celltrion has 11 approved biosimilars across immunology, oncology, hematology, ophthalmology and bone health - including Truxima (rituximab), Herzuma (trastuzumab), Yuflyma (adalimumab), Vegzelma (bevacizumab), Omlyclo (omalizumab, the first and only FDA-approved interchangeable biosimilar to Xolair), Eydenzelt (aflibercept), Steqeyma (ustekinumab), Stoboclo/Osenvelt (denosumab) and Avtozma (tocilizumab) - alongside regulatory approvals from FDA, EMA, MFDS, Health Canada, PMDA and others.

Celltrion generates revenue through direct sales of biosimilars and novel biologics across approximately 100 countries via wholly owned subsidiaries (Celltrion USA, Celltrion Healthcare Japan, Celltrion Healthcare Europe, Gifrer in France), supplemented by a contract manufacturing/CDMO business that includes a 678.7 billion won agreement with Eli Lilly through 2029 and additional deals representing a cumulative backlog above 1 trillion won. End customers span hospital systems, government healthcare programs, retail pharmacies and payers (with Zymfentra achieving reimbursement coverage across >90% of the US insured market), while the company invests heavily in capacity (1.23 trillion won Songdo Plants 4&5, plus Branchburg expansion) and AI-augmented R&D to convert the platform into a full one-stop biopharma solution.

Name

Celltrion

Legal name

Celltrion Inc.

Website

https://www.celltrion.com

Company type

Public

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

Celltrion is a South Korean biopharmaceutical company that develops, manufactures and globally commercializes monoclonal antibody biosimilars, novel biologics and small molecules, serving hospital systems, payers and patients across roughly 100 countries from manufacturing bases in Songdo and Branchburg, New Jersey.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

Keywords

• Biosimilar development
• Monoclonal antibody manufacturing
• Biopharmaceutical contract manufacturing
• Novel therapeutic biologics
• Antibody drug conjugates

Headquarters

HQ city

Incheon

HQ country

South Korea

HQ region

Asia

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Biosimilar Product Sales: Celltrion generates revenue primarily from selling biosimilar products globally, including Remsima, Truxima, Herzuma, Yuflyma, Vegzelma, Omlyclo, Eydenzelt, Steqeyma, Stoboclo/Osenvelt, and Avtozma across immunology, oncology, and other therapeutic areas
2. Novel Therapeutics Sales: Sales of novel biologic drugs including Zymfentra (subcutaneous infliximab) for inflammatory bowel disease and Regkirona for COVID-19
3. Contract Manufacturing (CMO/CDMO): Celltrion provides contract manufacturing services for drug substance and drug product to global pharmaceutical companies, including agreements with Eli Lilly worth approximately 678.7 billion won through 2029 and additional contracts with undisclosed global pharma companies
4. Small Molecule Products: Sales of generic pharmaceutical products and improved new drugs including CT-G07 (HIV/AIDS treatment) and Donerion Patch (Alzheimer's dementia)

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Celltrion researches, develops, manufactures, and commercializes biosimilar and novel biopharmaceutical products—including monoclonal antibody biosimilars, subcutaneous biologics, antibody-drug conjugates, and small molecule drugs—using proprietary animal cell culture and antibody engineering technologies. The company provides one-stop biopharmaceutical solutions spanning R&D, clinical trials, regulatory affairs, production, and global distribution, and offers contract development and manufacturing (CDMO) services to other pharmaceutical companies.

Product overview

Celltrion is a global biopharmaceutical company offering a diversified portfolio of biosimilars, novel therapeutics, and contract manufacturing services. The biosimilar portfolio includes 11 approved products: Remsima (infliximab), Truxima (rituximab), Herzuma (trastuzumab), Yuflyma (adalimumab), Vegzelma (bevacizumab), Omlyclo (omalizumab), Eydenzelt (aflibercept), Steqeyma (ustekinumab), Stoboclo/Osenvelt (denosumab), and Avtozma (tocilizumab). Novel therapeutics include Zymfentra (subcutaneous infliximab - the world's only SC infliximab formulation) and Regkirona (COVID-19 treatment). The pipeline includes obesity candidates CT-G32 (quadruple-action injectable, IND H1 2027) and oral formulation (IND H2 2028), ADC candidate CT-P70, bispecific antibody ABP-102/CT-P72 (Phase 1), and biosimilar candidates CT-P44, CT-P51, CT-P53, CT-P55. Small molecule portfolio includes CT-G07 (HIV) and Donerion Patch (Alzheimer's). CDMO services offered for antibody drug substance manufacturing, aseptic filling, and mRNA services. Manufacturing facilities in Songdo, Korea (250,000L capacity) and Branchburg, NJ (66,000L, expanding to 141,000L) with total planned capacity of 571,000L.

Differentiator

Problem solved

Functional benefit

Brands

• Remsima: Infliximab biosimilar for rheumatoid arthritis and inflammatory bowel disease
• Truxima
• Herzuma
• Yuflyma
• Vegzelma
• Omlyclo
• Eydenzelt
• Steqeyma
• Stoboclo/Osenvelt
• Avtozma
• Zymfentra
• Regkirona

Products and services

• Remsima Infliximab biosimilar for treating rheumatoid arthritis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), and other autoimmune conditions. Approved by EMA, FDA, and MFDS. Remsima held 68% market share across Europe in Q3 2025.
• Remsima SC Subcutaneous formulation of infliximab for autoimmune diseases. World's first subcutaneous infliximab formulation. Holds 31% market share in EU5 countries as of Q4 2025.
• Truxima Rituximab biosimilar for treating Non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other CD20-positive B-cell malignancies and autoimmune diseases. Approved by EMA, FDA, and MFDS.
• Herzuma Trastuzumab biosimilar for treating HER2-positive metastatic breast cancer, metastatic gastric cancer, and other HER2-positive cancers. Approved by EMA, FDA, and MFDS.
• Yuflyma Adalimumab biosimilar (referencing Humira) for treating rheumatoid arthritis, inflammatory bowel disease, psoriasis, and other autoimmune conditions. Approved by EMA, FDA, and MFDS.
• Vegzelma Bevacizumab biosimilar (referencing Avastin) for treating metastatic colorectal cancer, non-small cell lung cancer, renal cell carcinoma, and other VEGF-mediated cancers. Approved by EMA, FDA, and MFDS.
• Omlyclo Omalizumab biosimilar (referencing Xolair) for treating asthma, chronic spontaneous urticaria, and allergic conditions. First and only FDA-approved interchangeable biosimilar to Xolair. Approved in EU, US, and other markets.
• Eydenzelt Aflibercept biosimilar (referencing Eylea) for treating diabetic macular edema, wet age-related macular degeneration, and other ophthalmic conditions. Approved in EU, Canada, and Korea.
• Steqeyma Ustekinumab biosimilar (referencing Stelara) for treating plaque psoriasis, psoriatic arthritis, Crohn's disease, and other autoimmune conditions. Approved in EU, US, Japan, and over 40 countries.
• Stoboclo/Osenvelt Denosumab biosimilar (referencing Prolia/Xgeva) for treating osteoporosis and bone metastases. Approved in EU and US. Included in CVS Caremark formulary replacing Amgen's Prolia.
• Avtozma Tocilizumab biosimilar (referencing Actemra) for treating rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome. Available in both IV and SC formulations.
• Zymfentra Subcutaneous infliximab formulation (infliximab-dyyb) - the world's only and first FDA-approved subcutaneous formulation of infliximab. Novel biologic approved via BLA 351(a) pathway for maintaining remission in ulcerative colitis and Crohn's disease. US prescription rate tripled year-on-year in Q1 2026.
• Regkirona Regdanvimab monoclonal antibody for treating COVID-19. Approved by Korean MFDS and European EMA.
• CT-G07 Small molecule drug for HIV/AIDS treatment. Approved by FDA and WHO.
• Donerion Patch Transdermal patch formulation for treating Alzheimer's dementia symptoms. Approved by MFDS.
• CDMO Services

Quantifiable outcome

• 68% market share for Remsima in Europe
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Eleven partnerships are on record, tiered minor, core and major.

• Seoul Bio HubminorStrategic or Co-development Partner · 10 June 2026Open innovation program partnership with Seoul Bio Hub to identify early-stage companies with technologies that could complement Celltrion's R&D efforts. Fourth cohort selected includes AinB, Enbiocell, Imita Science, and Podo Therapeutics. Previous cohort companies including Enterobiome and Biomi secured investments and entered research partnerships with Celltrion.
• Scohia PharmacoreStrategic or Co-development Partner · 29 May 2026Strategic collaboration with Japan-based Scohia Pharma to support development of CT-G32, Celltrion's next-generation obesity drug candidate. Celltrion expected to lead global development and commercialization while Scohia supports research activities.
• Seoul Bio Hub (National Antibody Cluster partnership)minorStrategic or Co-development Partner · 3 April 2026Hongcheon National Antibody Cluster partnership supporting bio-industry development and open innovation programs with large enterprises including Celltrion, Dong-A ST, and others.
• KoBioLabscoreStrategic or Co-development Partner · 25 March 2026License-in agreement with Korean biopharma company KoBioLabs for three microbiome-based drug candidates targeting intestinal diseases. Deal valued at up to 205.2 billion won ($136.8 million), granting Celltrion exclusive rights to develop and commercialize candidates aimed at gastrointestinal conditions such as IBS-D.
• CMIC Group (Celltrion Healthcare Japan partnership)coreStrategic or Co-development Partner · 17 March 2026Celltrion Healthcare Japan and CMIC Group signed comprehensive business partnership agreement to jointly expand Celltrion's biosimilar business in Japan. Partnership combines Celltrion's global biosimilar R&D and product portfolio with CMIC's end-to-end pharmaceutical value chain support spanning development, manufacturing, and sales in Japan.
• Undisclosed Global Pharmaceutical CompanymajorImplementation/ SI/ Consulting Partner · 17 March 2026Contract manufacturing agreement for drug substance worth up to 294.9 billion won (potentially expandable to 375.4 billion won) with undisclosed global pharmaceutical company. Contract runs from March 2026 through 2029, representing approximately 8.3% of Celltrion's recent sales.
• GaluxcoreTechnology or Integration · 9 February 2026Celltrion partnered with AI startup Galux to develop multispecific antibody drugs for autoimmune diseases. Galux focuses on AI-based antibody design using its GaluxDesign platform, while Celltrion handles preclinical and clinical development to accelerate drug development and improve success rates.
• Abpro HoldingscoreStrategic or Co-development Partner · 6 January 2026Co-development partnership with Abpro for multispecific antibody drugs. FDA cleared IND application for ABP-102/CT-P72, a HER2 × CD3 bispecific T-cell engager for HER2-positive solid tumors, enabling Phase 1 clinical trial initiation in first half of 2026.
• Eli LillycoreImplementation/ SI/ Consulting Partner · 2 January 2026Contract manufacturing agreement with Eli Lilly worth approximately 678.7 billion won through 2029 for drug substance production. Celltrion acquired Eli Lilly's Branchburg, New Jersey manufacturing facility and provides CMO services under a long-term supply agreement.
• Korean Conglomerates (Samsung, Hyundai, SK, LG)minorOthers · 30 November 2025Participation in South Korea's domestic investment initiatives alongside Samsung Electronics, Hyundai Motor Group, SK Group, and LG Group. Companies pledged substantial investments in Korea's technology, manufacturing, and R&D sectors following discussions with President Lee Jae-myung.
• BioMeminorStrategic or Co-development Partner · 1 June 2025Joint development partnership with BioMe for BM111, a microbiome-based live biotherapeutic product. IRB approval received for clinical trials, with Celltrion supporting joint development activities.

Scale indicators15 records

Recent moves11 records

Expansion highlights8 records

Emerging players

• Bio-Thera Solutions: China-based biosimilar developer (Qletli, Hertimab) pursuing FDA approvals for adalimumab, bevacizumab, and trastuzumab; an emerging direct competitor in markets where Celltrion's Yuflyma, Vegzelma, and Herzuma are already established.
• Innovent Biologics: China-based biologics company (Tyvyt, BYVASDA, sintilimab) with growing biosimilar and CDMO ambitions; an emerging player expanding into international markets where Celltrion has a multi-year head start.

Direct peers

• Alvotech: Iceland-based pure-play biosimilar developer focused on adalimumab, ustekinumab, and aflibercept with vertically integrated manufacturing; a direct head-to-head competitor in the markets where Celltrion's Yuflyma, Steqeyma, and Eydenzelt compete.
• Biocon Biologics: India-based biosimilar leader (Ogivri, Fulphila, Semglee) with Viatris-distributed global reach; competes with Celltrion in trastuzumab, pegfilgrastim, insulin glargine, and increasingly in immunology biosimilars.
• WuXi Biologics: Global biologics CDMO and biosimilar developer with the largest contract manufacturing capacity outside of Korea; provides both competing CDMO services and develops biosimilars that overlap Celltrion's pipeline and contract offerings.
• Samsung Bioepis (Samsung Biologics): Korean-headquartered biosimilar developer (Benepali, Imraldi, Ontruzant, Hadlima, etc.) with massive Samsung Biologics manufacturing scale; competes head-to-head with Celltrion in infliximab, adalimumab, and trastuzumab markets across the US, EU, and Asia.

Broad incumbents

• Lonza Group: Swiss-based global CDMO leader offering mammalian and microbial biologics manufacturing at scale; competes with Celltrion's BioSolutions CDMO business for pharma clients outsourcing antibody drug substance and aseptic fill-finish.
• Amgen: Originator of many of the biologics Celltrion is biosimilaring (Remicade, Neulasta, Soliris) and now competing in biosimilars (Amjevita, Kanjinti) through its US distribution muscle and deep payer relationships; a benchmark incumbent shaping biosimilar market dynamics.
• Sandoz Group: World's largest biosimilars pure-play (Hyrimoz, Erelzi, Zessly, Omnitrope) spun out of Novartis; a broad incumbent with global commercial reach and a deep biosimilar pipeline that competes directly with Celltrion across most major molecules.
• Pfizer (Hospira / biosimilars): Major originator-and-biosimilar player (Inflectra/Remsima rival, Nivestym, Retacrit, Trazimera) with deep US payer access post-Hospira; competes with Celltrion on infliximab, rituximab, trastuzumab, and pegfilgrastim in the US and EU.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/celltriondream
• Facebookfacebook.com/celltriondream
• LinkedInlinkedin.com/company/celltrion
• Instagraminstagram.com/celltrion_global

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celltrion